Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Pan Afr Med J ; 36: 367, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33235644

RESUMO

Lysosomial diseases and autoimmune diseases are systemic disorders. Their clinical manifestations can overlap with the broad spectrum of one another. Their association has been rarely reported. We report a new case of systemic lupus erythematous (SLE) associated to antiphospholipid syndrome (APS) and Hashimoto thyroiditis occurring in Niemann-Pick disease (NPD) type B patient. A 42-year-old woman with a familial history of NPD was diagnosed with a NPD type B at the age of ten. Twenty years later (2008), she complained of inflammatory arthralgia with acute dyspnea. She was diagnosed with SLE (according to ACR criteria) and Hashimoto disease with positive IgG anti-cardiolipin and IgA anti-beta2 glycoprotein. In 2018, she presented a left segmental pulmonary embolism. Antiphospholipid syndrome was retained. She was treated with steroids, hydroxychloroquine, anticoagulation therapy and levothyroxine. Her SLE treatment was re-enforced by cyclophosphamide because of corticosteroid dependence and recurrent hemolytic crises.


Assuntos
Síndrome Antifosfolipídica/diagnóstico , Doença de Hashimoto/diagnóstico , Lúpus Eritematoso Sistêmico/diagnóstico , Doenças de Niemann-Pick/diagnóstico , Adulto , Síndrome Antifosfolipídica/tratamento farmacológico , Dispneia/etiologia , Feminino , Doença de Hashimoto/tratamento farmacológico , Humanos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Doenças de Niemann-Pick/tratamento farmacológico , Embolia Pulmonar/diagnóstico , Tomografia Computadorizada por Raios X
2.
Eur J Clin Pharmacol ; 74(6): 711-722, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29479633

RESUMO

PURPOSE: We aimed to study potential variables involved in interindividual variability to acenocoumarol (AC) response in order to establish a pharmacogenetic algorithm (PA) that includes clinical and genetic factors to predict adequate AC dose to stabilize anticoagulation in a cohort of Tunisian patients. METHODS: Genotyping of the CYP2C9, VKORC1, CYP4F2, and CALU polymorphisms was conducted on 246 patients using PCR-RFLP technique. AC normalized maintenance dose (NMD): ((mean maintenance dose/international normalized ratio (INR)) equilibrium) was calculated. The statistical study was carried out with SPSS V20. RESULTS: A significant correlation was found between age, BMI, and daily AC dose (r = - 0.397; p < 0.001 and r = 0.215; p = 0.001, respectively). The carriers of mutated alleles CYP2C9*2 or CYP2C9*3 or VKORC1 haplotypes (H1 and H7) were associated with AC hyper-sensibility. After adjustment to potential covariates, these patients presented supra-therapeutic INR during treatment period and needed low AC dose (ORs* = 0.28 [0.06-0.60], p = 0.004; ORs* = 0.12 [0.04-0.05], p < 0.001; ORs* = 0.45 [0.24-0.84], p = 0.01; and ORs* = 0.28 [0.06-0.98], p = 0.049, respectively). However, carriers of VKORC1 haplotypes (H3 and H12) or mutated alleles CYP4F2 (rs2108622) or CALU (rs1043550) tend to resist to treatment, hence long period of therapy initiation, and must be treated with high AC dose (ORs* = 2.67 [81.12-5.91], p = 0.013; ORs* = 8.76 [1.07-76.26], p = 0.019; ORs* = 3.12 [1.01-9.63], p = 0.047; and ORs* = 3.96 [1.41-11.09], p = 0.009, respectively). A final multivariate regression model explained 48.1% of the global interindividual variability in AC dose requirement. CONCLUSION: The PA demonstrated that VKORC1 and CYP2C9 polymorphisms contribution was more important than clinical factors. Applying the PA would allow dose adjustment to treat patients in a personalized manner.


Assuntos
Acenocumarol/administração & dosagem , Anticoagulantes/administração & dosagem , População Negra/genética , Citocromo P-450 CYP2C9/genética , Vitamina K Epóxido Redutases/genética , Acenocumarol/efeitos adversos , Acenocumarol/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Anticoagulantes/efeitos adversos , Anticoagulantes/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Fibrilação Atrial/genética , Proteínas de Ligação ao Cálcio/genética , Família 4 do Citocromo P450/genética , Feminino , Genótipo , Hemorragia , Humanos , Coeficiente Internacional Normatizado , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único , Tunísia , Trombose Venosa/tratamento farmacológico , Trombose Venosa/genética , Adulto Jovem
3.
Pan Afr Med J ; 27: 160, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28904688

RESUMO

Cellulitis is a frequent soft tissue and skin infection. The lower limbs are affected in 70 to 80% of cases. Cellulitis in aged persons is not yet well described in literature. A retrospective descriptive study conducted in the Internal Medicine Department of Sahloul hospital in Sousse in Tunisia. It included patients whose age was up to 65 years old admitted into hospital for cellulitis of the legs, the arms or the face. One hundred fifty eight patients with a mean age of 73 years old (range: 65 to 94 years old) were included. Female to male sex ratio was 0.68. Among them, we noted diabetes mellitus in 81 cases (50.6%). The infection was located in the lower limbs in 155 cases (98%), in the face in two cases (1.3%) and in the upper limb in one case (0.7%). Twenty one patients (13.3%) presented with severe cellulitis and one presented with necrotizing fasciitis. All patients received intra venous antibiotic therapy. Surgical treatment was indicated in 14 cases. Cefazolin was prescribed in 77 cases (48%). Favorable evolution was noted in 144 patients (91.1%). Forty four patients (27.8%) received prophylactic antibiotics. Prevention of skin and soft tissue infection is a crucial step to preserve health in aged persons.


Assuntos
Antibacterianos/uso terapêutico , Celulite (Flegmão)/epidemiologia , Fasciite Necrosante/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Antibioticoprofilaxia/métodos , Braço , Celulite (Flegmão)/terapia , Face , Feminino , Hospitalização , Humanos , Perna (Membro) , Masculino , Estudos Retrospectivos , Índice de Gravidade de Doença , Distribuição por Sexo , Tunísia/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA